Enrico Jones, MD
Pain Medicine · Greensboro, NCNPI 1245291863
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $672 and has fallen 54.0% since, to $309 in 2025. That places this record below the midpoint for pain medicine clinicians in NC, where the typical reported total is $3,846.
Across 170 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$620
- Lilly USA, LLC$506
- AbbVie$273
- Amarin Pharma, Inc.$217
- Pfizer$156
- Boehringer Ingelheim$110
- plus $966 from 20 others
Across 16 payments — averaging $2168.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$35K
What the payments were for
- Travel & lodging$151%
- Food & beverage$2,83099%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $620 |
| Lilly USA, LLC | 29 | $506 |
| AbbVie | 15 | $273 |
| Amarin Pharma, Inc. | 16 | $217 |
| Pfizer | 9 | $156 |
| Boehringer Ingelheim | 6 | $110 |
| Shield Therapeutics Inc | 6 | $93 |
| GSK | 5 | $89 |
| Exact Sciences | 1 | $82 |
| Forte Bio-pharma LLC | 3 | $79 |
| Optinose US, Inc. | 5 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $71 |
| Merck | 5 | $70 |
| Collegium Pharmaceutical, Inc. | 3 | $57 |
| Amgen | 3 | $53 |
| Scilex Pharmaceuticals Inc. | 2 | $45 |
| Genentech USA, Inc. | 3 | $44 |
| Orexo US, Inc. | 2 | $39 |
| AstraZeneca | 2 | $36 |
| Bayer | 2 | $25 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Tris Pharma Inc | 1 | $19 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $13 |
How this compares
$2,848 in reported general payments places this provider in the 40th percentile of 182 pain medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 31 | $46,554 |
| JanuviaSitagliptin Phosphate | 35 | $43,699 |
| JardianceEmpagliflozin | 30 | $35,518 |
| OzempicSemaglutide | 29 | $32,713 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $30,550 |
| FarxigaDapagliflozin Propanediol | 20 | $25,145 |
| EliquisApixaban | 16 | $20,274 |
| BelbucaBuprenorphine Hcl | 19 | $17,238 |
| Xtampza ErOxycodone Myristate | 21 | $14,131 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 186 | $9,017 |
| Naloxone Hcl | 128 | $7,361 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $5,097 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $4,132 |
| Oxycodone Hcl | 176 | $3,539 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 82 | $3,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $70 | $74,24963 claims |
| Lilly USA, LLCMounjaro | $506 | $46,55431 claims |
| Boehringer IngelheimJardiance | $110 | $35,51830 claims |
| Novo NordiskOzempic | $620 | $32,71329 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $57 | $31,36940 claims |
| AstraZenecaFarxiga | $36 | $25,14520 claims |
| PfizerEliquis | $156 | $20,27416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 182 pain medicine providers in North Carolina.
Other pain medicine in Greensboro
- Kyle SebastianGreensboro$14K
- Dave EichmanGreensboro$12K
- Yun SunGreensboro$9K
- James NorthWinston Salem$721K
- Leonardo KapuralWinston Salem$523K
- Christopher GilmoreWinston Salem$457K
- Richard RauckWinston Salem$431K
- Courtney AumanJacksonville$186K
- Jacob WangCharlotte$162K
- Aashish KumarCharlotte$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.